[11C]5-Hydroxy-tryptophan PET for Assessment of Islet Mass in Type 2 Diabetes

Per-Ola Carlsson39 enrolled

Overview

Cross-sectional study to investigate subjects at different stages of type 2 diabetes development with expected stratification of pancreatic islet mass. Non-diabetic individuals were assigned as control. The primary outcome was the \[11C\]5-hydroxy-tryptophan uptake and retention in the pancreas as a surrogate marker for the endogenous islet mass.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Type2 Diabetes

Interventions

Positron emission tomography with the tracer [11C]5-hydroxy-tryptophanRADIATION

Estimation of islet mass by PET using the tracer \[11C\]5-hydroxy-tryptophan

Eligibility

Sex: ALLHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Type 2 diabetes fulfilling criteria for the four different study groups, or healthy volunteers Exclusion Criteria: * Ongoing pregnancy * Renal failure (GFR\<60 ml/min) * Magnetic metal parts in the body * Ongoing treatment with selective serotonin receptor inhibitors

Outcomes

Primary Outcomes

[11C]5-hydroxy-tryptophan Uptake in the Pancreas

Uptake of tracer with correlation to functional measurement with glucose-potentiated arginine stimulation of insulin release